These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30229462)

  • 1. Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation.
    Cicero AFG; Fogacci F; Bove M; Ventura F; Giovannini M; Borghi C
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):355-359. PubMed ID: 30229462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
    Núñez-Cortés JM
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():31-4. PubMed ID: 25043545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
    Hernández Mijares A
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():25-30. PubMed ID: 25043544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
    Díaz Rodríguez Á
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence.
    Barrios V; Escobar C; Cicero AF; Burke D; Fasching P; Banach M; Bruckert E
    Atheroscler Suppl; 2017 Feb; 24():1-15. PubMed ID: 27998714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus.
    Ruscica M; Gomaraschi M; Mombelli G; Macchi C; Bosisio R; Pazzucconi F; Pavanello C; Calabresi L; Arnoldi A; Sirtori CR; Magni P
    J Clin Lipidol; 2014; 8(1):61-8. PubMed ID: 24528686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
    Grandi AM; Nicolini E; Rizzi L; Caputo S; Annoni F; Cremona AM; Marchesi C; Guasti L; Maresca AM; Grossi P
    J Int AIDS Soc; 2014; 17(1):19004. PubMed ID: 25148829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
    Lemieux I; Laperrière L; Dzavik V; Tremblay G; Bourgeois J; Després JP
    Atherosclerosis; 2002 Jun; 162(2):363-71. PubMed ID: 11996956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia.
    Ducobu J; VanHaelst L; Salomon H
    J Cardiovasc Pharmacol; 2003 Jan; 41(1):60-7. PubMed ID: 12500022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy studies].
    Pedro-Botet J; Flores-Le Roux JA
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():17-9. PubMed ID: 25043542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
    Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
    Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.
    Farnier M; Marcereuil D; De Niet S; Ducobu J; Steinmetz A; Retterstøl K; Bryniarski L; Császár A; Vanderbist F
    Clin Drug Investig; 2012 Apr; 32(4):281-91. PubMed ID: 22350498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC; Faulds D
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
    Gerber JG; Kitch DW; Fichtenbaum CJ; Zackin RA; Charles S; Hogg E; Acosta EP; Connick E; Wohl D; Kojic EM; Benson CA; Aberg JA
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):459-66. PubMed ID: 17971707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
    Aberg JA; Zackin RA; Brobst SW; Evans SR; Alston BL; Henry WK; Glesby MJ; Torriani FJ; Yang Y; Owens SI; Fichtenbaum CJ;
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):757-67. PubMed ID: 16218799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.